Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viridian TherapeuticsVRDN +1.69%49 Buyback Yield % is -18.77 as of Aug. 11, 2026. GuruFocus rates VRDN with a GF Score™ of 49/100. The stock has 5 warning signs investors should review. Among 725 Biotechnology companies, Viridian Therapeutics ranks worse than 64.97% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Viridian Therapeutics Buyback Yield % Related Terms
Viridian Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Viridian Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VRDN vs BHVN, AGIO, SION: Buyback Yield % Comparison
For the Biotechnology subindustry, Viridian Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viridian Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (VRDN) has a Buyback Yield % of -18.77 as of Aug. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Viridian Therapeutics and its competitors. According to the industry distribution chart, Viridian Therapeutics ranks #471 out of 725 companies in the Biotechnology industry, placing it in the top 65%.
Is Viridian Therapeutics' Buyback Yield % too high?
Viridian Therapeutics' current Buyback Yield % is -18.77. Based on the distribution chart, Viridian Therapeutics ranks #471 out of 725 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viridian Therapeutics has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Buyback Yield % compare to BHVN and AGIO?
According to the Biotechnology industry distribution chart, Viridian Therapeutics ranks #471 out of 725 companies for Buyback Yield %. This places Viridian Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current Buyback Yield % is -18.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (VRDN) has a current Buyback Yield % of -18.77. The current Buyback Yield % is -18.77. Viridian Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Viridian Therapeutics (VRDN), the current Buyback Yield % is -18.77 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
49GF Score
Get the complete analysis for VRDN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRDN has been successfully added to your 
